| 索拉非尼治疗晚期原发性肝癌18例疗效及不良反应分析 |
| |
| 引用本文： | 崔勇霞,罗执芬,周建炜,周云. 索拉非尼治疗晚期原发性肝癌18例疗效及不良反应分析[J]. 实用临床医药杂志, 2011, 15(23): 83-84 |
| |
| 作者姓名： | 崔勇霞 罗执芬 周建炜 周云 |
| |
| 作者单位： | 河南省人民医院肿瘤内科,河南郑州,450003 |
| |
| 摘 要： | 目的评价索拉非尼治疗晚期肝细胞性肝癌的疗效及安全性。方法总结2009年10月~2011年6月本科应用索拉非尼治疗的18例晚期原发性肝癌患者的临床资料。观察其临床疗效、平均病情进展时间、6个月及1年生存率、生存质量和不良反应。结果服药8周后,18例患者均为稳定(100.00%);服药后16周后,1例患者腹水消失,为部分缓解(5.56%),13例为稳定(72.22%),4例为进展(22.22%)。平均服用索拉非尼时间11.9月,平均病情进展时间5.8个月。6个月生存率94.44%(17/18),1年生存率50.00%(9/18)。生存质量改善6例(33.33%),稳定8例(44.44%),下降4例(22.22%)。大多数患者为1~2级毒副反应。结论索拉非尼可提高晚期肝细胞性肝癌患者的6个月及1年生存率,且耐受性良好。
|
| 关 键 词： | 索拉非尼 晚期原发性肝癌 毒副反应 |
Analysis of effects and adverse reactions of Sorafenib on 18 cases with advanced hepatocellular carcinoma |
| |
| CUI Yong-xia , LUO Zhi-fer , ZHOU Jian-wei , ZHOU Yun. Analysis of effects and adverse reactions of Sorafenib on 18 cases with advanced hepatocellular carcinoma[J]. Journal of Clinical Medicine in Practice, 2011, 15(23): 83-84 |
| |
| Authors: | CUI Yong-xia LUO Zhi-fer ZHOU Jian-wei ZHOU Yun |
| |
| Affiliation: | (Henan Provincial People′s Hospital,Zhengzhou,Henan,450003) |
| |
| Abstract: | Objective To evaluate the efficacy and adverse reactions of Sorafenib in the treatment of advanced hepatocellular carcinoma.Methods The clinical data of 18 cases with hepatocellular carcinoma who were treated with Sorafenib from October 2009 to June 2011 were summarized.The objective effect,progression time,survival rate of six months and one year,quality of life and adverse reactions were evaluated during the treatment.Results After 8 weeks,18 patients achieved SD(100.00%).After 16 weeks,one patient receiv... |
| |
| Keywords: | Sorafenib advanced hepatocellular carcinoma adverse reactions |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
